Atlas Trials

Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib

Clinical trial NCT00474786 · COMPLETED

Trial details

NCT number
NCT00474786
Sponsor
Pfizer
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Renal Cell Carcinoma
Start date
2007-09-01
Primary completion
2012-01-01
Enrollment
512

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.